Tevogen (TVGN) Return on Capital Employed (2023 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Return on Capital Employed came in at 809.66% in Q1 2026, up 11498.0% YoY from N/an in Q1 2025, and down 18.54% on a QoQ basis from 993.88% in Q4 2025.
Tevogen (TVGN) Return on Capital Employed (2023 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 4 years of Return on Capital Employed data on file, last reported at 809.66% in Q1 2026.
- Quarterly Return on Capital Employed rose 11498.0% year-over-year to 809.66% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 809.66% (up 11498.0% YoY) and the FY2025 annual result came in at 830.87%, down 34402.0% from the prior year.
- Return on Capital Employed declined to 809.66% in Q1 2026, from 993.88% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 1311.32% in Q3 2025 to a low of 12.72% in Q4 2023.
- A 4-year average of 774.0% and a median of 799.58% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 102392 bps — and 2025, when it plunged 10542 bps.
- Tracing TVGN's Return on Capital Employed over 4 years: stood at 12.72% in 2023, then surged by 8050 bps to 1036.64% in 2024, then dropped by 4 bps to 993.88% in 2025, then dropped by 19 bps to 809.66% in 2026.
- The last three Return on Capital Employed figures came in at 809.66% (Q1 2026), 993.88% (Q4 2025), and 1311.32% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 809.66% |
| Dec 31, 2025 | 993.88% |
| Sep 30, 2025 | 1,311.32% |
| Jun 30, 2025 | 799.06% |
| Mar 31, 2025 | 694.68% |
| Dec 31, 2024 | 1,036.64% |
| Sep 30, 2024 | 698.48% |
| Jun 30, 2024 | 583.50% |
| Mar 31, 2024 | 800.10% |
| Dec 31, 2023 | 12.72% |